Dana Farber Cancer Institute
Boston, Massachusetts, United States
189 recruiting
Showing 1–20 of 234 trials
Recruiting
Phase 1
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Solid Tumor
Genentech, Inc.410 enrolled38 locationsNCT06619587
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Leukemia
Janssen Research & Development, LLC420 enrolled103 locationsNCT04811560
Recruiting
Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Solid Tumors
Incyte Corporation710 enrolled37 locationsNCT06179160
Recruiting
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients
Colorectal CarcinomaLynch Syndrome
Mayo Clinic750 enrolled9 locationsNCT05410977
Recruiting
Phase 2
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaHormone Receptor-Positive Breast Carcinoma+1 more
City of Hope Medical Center43 enrolled6 locationsNCT04305834
Recruiting
Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled205 locationsNCT05827081
Recruiting
Phase 3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Chronic Graft Versus Host Disease
Incyte Corporation240 enrolled119 locationsNCT06585774
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche230 enrolled192 locationsNCT05894239
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Phase 3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals450 enrolled142 locationsNCT05939414
Recruiting
Phase 1Phase 2
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Myeloid Leukemia, Philadelphia Positive
Novartis Pharmaceuticals34 enrolled39 locationsNCT04925479
Recruiting
Phase 2Phase 3
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Prostate Cancer
Novartis Pharmaceuticals443 enrolled72 locationsNCT06780670
Recruiting
Phase 2Phase 3
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma
Global Coalition for Adaptive Research2,250 enrolled63 locationsNCT03970447
Recruiting
Phase 2
ETHAN - ET for Male BC
Hormone Receptor-Positive Breast CancerMale Breast CancerHormone Receptor-Negative Breast Carcinoma
Jose Pablo Leone60 enrolled8 locationsNCT05501704
Recruiting
Phase 2
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Breast CancerTriple-Negative Breast CancerPD-L1 Negative
Dana-Farber Cancer Institute110 enrolled15 locationsNCT04468061
Recruiting
Phase 1Phase 2
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
Relapsed / Refractory Osteosarcoma
Lantheus Medical Imaging55 enrolled2 locationsNCT07357519
Recruiting
Phase 2
Ivosidenib as Post-HSCT Maintenance for AML
Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled4 locationsNCT06707493
Recruiting
Phase 1Phase 2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Cancer
Dana-Farber Cancer Institute38 enrolled1 locationNCT03310879
Recruiting
Phase 2
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
VEXAS SyndromeVEXAS
Swedish Orphan Biovitrum78 enrolled39 locationsNCT06782373